AR109250A1 - Métodos de uso y combinaciones farmacéuticas de inhibidores de hdac con inhibidores de proteínas bet - Google Patents
Métodos de uso y combinaciones farmacéuticas de inhibidores de hdac con inhibidores de proteínas betInfo
- Publication number
- AR109250A1 AR109250A1 ARP170101598A ARP170101598A AR109250A1 AR 109250 A1 AR109250 A1 AR 109250A1 AR P170101598 A ARP170101598 A AR P170101598A AR P170101598 A ARP170101598 A AR P170101598A AR 109250 A1 AR109250 A1 AR 109250A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Reivindicación 1: Un método para tratar un cáncer en un sujeto que lo necesita, que comprende administrarle al sujeto una cantidad terapéuticamente eficaz de un inhibidor selectivo de la histona desacetilasa 6 (HDAC6) y una cantidad terapéuticamente eficaz de un inhibidor de las proteínas con dominios con bromo y motivos adicionales en los extremos (BET). Reivindicación 2: El método de la reivindicación 1, donde el inhibidor selectivo de HDAC6 es un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de éste, donde el anillo B es arilo o heteroarilo; R¹ es arilo o heteroarilo opcionalmente sustituido con OH, halo o C₁₋₆-alquilo; y R es H o C₁₋₆-alquilo. Reivindicación 4: El método de la reivindicación 2, donde el compuesto de la fórmula (1) es un compuesto de fórmula (2) o una sal farmacéuticamente aceptable de éste. Reivindicación 6: El método de la reivindicación 2, donde el compuesto de fórmula (1) es un compuesto de fórmula (3) o una sal farmacéuticamente aceptable de éste. Reivindicación 7: El método de la reivindicación 1, donde el inhibidor selectivo de la HVDAC6 es un compuesto de fórmula (4), o una sal farmacéutica mente aceptable de éste; donde Rˣ y Rʸ, junto con el carbono al que están unidos, forman ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, cicloheptilo o ciclooctilo; cada Rᵃ es independientemente C₁₋₆-alquilo, C₁₋₆-alcoxilo, halo, OH, -NO₂, -CN o -NH₂; y m es 0, 1 ó 2. Reivindicación 8: El método de la reivindicación 7, donde el compuesto de fórmula (4) es un compuesto de fórmula (5) o una sal farmacéuticamente aceptable de éste. Reivindicación 9: El método de la reivindicación 7, donde el compuesto de fórmula (4) es un compuesto de fórmula (6) o una sal farmacéuticamente aceptable de éste. Reivindicación 10: El método de la reivindicación 1, donde el inhibidor selectivo de la HDAC6 es la tubastatina A, o una sal farmacéuticamente aceptable de ésta. Reivindicación 11: El método de cualquiera de las reivindicaciones precedentes, donde el inhibidor de las BET se selecciona del grupo que consiste en ABBV-075, BAY1238097, BMS986158, bromosporina, CBP30, CPI-203, CPI-0610,FT-1101, GSK2820151, I-BET151, I-BET726, I-BET-762, INCB054329, INCB057643, ISOX DUAL, JQ1, LY294002, LY303511, MS436, MK8628, OF-1, OXF BD 02, PFI-1, PFI-3, PF-6405761, RVX-208, TEN-010; XD 14, ZEN003694 o una sal farmacéuticamente aceptable de cualquiera de ellos. Reivindicación 15: Una combinación farmacéutica que comprende una cantidad terapéuticamente eficaz de un inhibidor selectivo de la HDAC6, o una sal farmacéuticamente aceptable de éste, y una cantidad terapéuticamente eficaz de un inhibidor de BET, o una sal farmacéuticamente aceptable de éste.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662348054P | 2016-06-09 | 2016-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109250A1 true AR109250A1 (es) | 2018-11-14 |
Family
ID=60578132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101598A AR109250A1 (es) | 2016-06-09 | 2017-06-09 | Métodos de uso y combinaciones farmacéuticas de inhibidores de hdac con inhibidores de proteínas bet |
Country Status (6)
Country | Link |
---|---|
US (1) | US11298354B2 (es) |
EP (1) | EP3468559B1 (es) |
JP (2) | JP7233220B2 (es) |
AR (1) | AR109250A1 (es) |
TW (1) | TW201803594A (es) |
WO (1) | WO2017214565A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2526093B1 (en) * | 2010-01-22 | 2016-08-17 | Acetylon Pharmaceuticals, Inc. | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
PL3442972T3 (pl) | 2016-04-15 | 2020-07-27 | Abbvie Inc. | Inhibitory bromodomeny |
US11497746B2 (en) | 2016-11-23 | 2022-11-15 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof |
KR102063397B1 (ko) * | 2018-04-27 | 2020-01-07 | 이화여자대학교 산학협력단 | Pfi-3를 포함하는 폐암 또는 대장암의 예방 또는 치료용 조성물 |
CN114908049A (zh) * | 2021-02-10 | 2022-08-16 | 江苏集萃医学免疫技术研究所有限公司 | Hdac6抑制剂在选择性诱导t细胞扩增中的用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2526093B1 (en) | 2010-01-22 | 2016-08-17 | Acetylon Pharmaceuticals, Inc. | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
WO2012018499A2 (en) * | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
JP2015515279A (ja) * | 2012-04-19 | 2015-05-28 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療 |
US8975417B2 (en) * | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
US20140357512A1 (en) * | 2013-06-03 | 2014-12-04 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase (hdac) biomarkers in multiple myeloma |
US9403779B2 (en) * | 2013-10-08 | 2016-08-02 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors |
EP3054954A4 (en) * | 2013-10-10 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
WO2015054474A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
ES2818933T3 (es) * | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
PE20161342A1 (es) * | 2013-10-11 | 2016-12-31 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
CA2932411A1 (en) * | 2013-12-03 | 2015-06-11 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
EP3084446B1 (en) * | 2013-12-20 | 2022-12-14 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma |
WO2015168587A1 (en) * | 2014-05-02 | 2015-11-05 | Oncoethix Sa | Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds |
CN107205988A (zh) | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
WO2016168647A1 (en) * | 2015-04-17 | 2016-10-20 | Acetylon Pharmaceuticals Inc. | Treatment of neuroblastoma with histone deacetylase inhibotrs |
AR105812A1 (es) * | 2015-06-08 | 2017-11-15 | Acetylon Pharmaceuticals Inc | Métodos para la preparación de inhibidores de proteína deacetilasa |
WO2016200919A1 (en) * | 2015-06-08 | 2016-12-15 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
EP3368026A1 (en) * | 2015-10-27 | 2018-09-05 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors for the treatment of diabetic peripheral neuropathy |
US11311540B2 (en) * | 2016-02-17 | 2022-04-26 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs |
JP2019515909A (ja) * | 2016-04-19 | 2019-06-13 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物 |
EP3532054A4 (en) * | 2016-10-28 | 2020-06-17 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLASE INHIBITOR AND EPOTHILON AND METHOD FOR USE THEREOF |
EP3532065B1 (en) * | 2016-10-28 | 2024-04-24 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof |
WO2018085652A1 (en) * | 2016-11-04 | 2018-05-11 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a bcl-2 inhibitor and methods of use thereof |
WO2018098348A1 (en) * | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a cd38 inhibitor and methods of use thereof |
US11497746B2 (en) * | 2016-11-23 | 2022-11-15 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof |
-
2017
- 2017-06-09 WO PCT/US2017/036847 patent/WO2017214565A1/en unknown
- 2017-06-09 EP EP17811118.3A patent/EP3468559B1/en active Active
- 2017-06-09 TW TW106119359A patent/TW201803594A/zh unknown
- 2017-06-09 US US16/305,567 patent/US11298354B2/en active Active
- 2017-06-09 AR ARP170101598A patent/AR109250A1/es unknown
- 2017-06-09 JP JP2018564262A patent/JP7233220B2/ja active Active
-
2022
- 2022-12-08 JP JP2022196402A patent/JP2023027220A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019521108A (ja) | 2019-07-25 |
EP3468559B1 (en) | 2023-11-22 |
US11298354B2 (en) | 2022-04-12 |
US20200323848A1 (en) | 2020-10-15 |
EP3468559A4 (en) | 2020-01-15 |
EP3468559A1 (en) | 2019-04-17 |
JP7233220B2 (ja) | 2023-03-06 |
TW201803594A (zh) | 2018-02-01 |
WO2017214565A1 (en) | 2017-12-14 |
JP2023027220A (ja) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109250A1 (es) | Métodos de uso y combinaciones farmacéuticas de inhibidores de hdac con inhibidores de proteínas bet | |
EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
CL2020001218A1 (es) | Compuestos útiles para inhibir a cdk7. | |
ECSP17054980A (es) | Inhibidores selectivos de bace1 | |
UY36121A (es) | ?pirazolopiridinas y pirazolopirimidinas?. | |
AR093705A1 (es) | Depsipeptido y sus usos | |
UY36153A (es) | ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos? | |
EA201791289A1 (ru) | Ингибиторы клеточного некроза и связанные с ними способы | |
TR201900057T4 (tr) | Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler. | |
CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
CO2018002483A2 (es) | Ciano tienotriazolpirazinas y usos de las mismas | |
PE20180412A1 (es) | Compuestos inhibidores de la senalizacion de la via de notch | |
MX2016014911A (es) | Acidos hidroxamicos heterociclicos como inhibidores de proteina desacetilasa e inhibidores dobles de proteina desacetilasa-proteina cinasa, y metodos de uso de los mismos. | |
AR103110A1 (es) | Métodos de combinación para el tratamiento de cánceres | |
BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
EA201692470A1 (ru) | Фармацевтические комбинации | |
NI202000058A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
AR101290A1 (es) | Inhibidores de aldosterona sintasa | |
UY36123A (es) | Derivados de carboxamida | |
CO2022002545A2 (es) | Proteínas de fusión terapéuticas | |
EA201991069A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |